Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Celyad Sa Ads (CYAD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Celyad Announces Closing of Global Offering

Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell based therapies, today announced the...

CYAD : 28.88 (-0.38%)
Celyad announces pricing of $47.3 million global offering

Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell based therapies, today announced the pricing...

CYAD : 28.88 (-0.38%)
Celyad Announces First Quarter 2018 Business Update

Steady progress in THINK, SHRINK and LINK trials

CYAD : 28.88 (-0.38%)
Celyad Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2018

Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) a clinical-stage biopharmaceutical company focused on the development of CART-cell therapies, today announced that the company will present recent...

CYAD : 28.88 (-0.38%)
Celyad Successfully Administers CYAD-01 in First Patients in SHRINK and LINK Trials

Celyad achieves important milestone in CYAD-01 treatment evaluation of metastatic colorectal cancer:

CYAD : 28.88 (-0.38%)
Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML Patient

Case report details first ever reported complete morphologic remission with gene

CYAD : 28.88 (-0.38%)
Global Stem Cells Market 2016-2018 & 2022 & Profiles of Cellular Dynamics International, Celyad, Cytori Therapeutics,, Epistem and Gamida-Cell

The "The Global Market for Stem Cells" report has been added to ResearchAndMarkets.com's offering.

CYTX : 2.39 (-8.08%)
CYAD : 28.88 (-0.38%)
Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018

Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CART-cell therapies, today announced that the company will present...

CYAD : 28.88 (-0.38%)
Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018

Conference call scheduled for Friday, 23 March, at 2:00 p.m. CET / 9:00 a.m. EDT

CYAD : 28.88 (-0.38%)
BioLife Solutions Executes Additional Long-Term Supply Agreement with Leading T Cell Therapy Customer

BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife"), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media,...

CYAD : 28.88 (-0.38%)
BLFS : 9.51 (+5.08%)
BLCM : 8.03 (+1.01%)
KITE : 179.99 (+0.11%)
Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference

Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced that Patrick Jeanmart, Chief Financial Officer and...

CYAD : 28.88 (-0.38%)
Celyad Announces Third Quarter 2017 Business Update

Celyad (Euronext Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell based therapies, today provided an update on...

CYAD : 28.88 (-0.38%)
Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial

-- First ever morphologic complete response (MLFS) with gene-engineered T cells without prior pre-conditioning chemotherapy for a patient with relapsed refractory acute myeloid leukemia (AML).

CYAD : 28.88 (-0.38%)
Celyad to Present at the Cantor Fitzgerald Global Healthcare Conference

Celyad (Euronext Brussels:CYAD) (Euronext Paris:CYAD) (NASDAQ:CYAD), a pioneer in the discovery and development of CAR-T cell therapies, today announced that Patrick Jeanmart, Chief Financial Officer and...

CYAD : 28.88 (-0.38%)
Featured Company News - BioLife Solutions Executes Supply Agreement with Celyad for CryoStor(R) Use in Natural Killer Receptor based T-Cell (NKR-T) Platform

Research Desk Line-up: Stryker Post Earnings Coverage

SYK : 175.04 (-0.22%)
CYAD : 28.88 (-0.38%)
BLFS : 9.51 (+5.08%)
BioLife Solutions Executes Supply Agreement with Celyad for CryoStor® Use in Natural Killer Receptor based T-Cell (NKR-T) Platform Targeting Solid Tumors and Blood Cancers

BOTHELL, Wash. , July 31, 2017 /PRNewswire/ --  BioLife Solutions , Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic...

CYAD : 28.88 (-0.38%)
BLFS : 9.51 (+5.08%)
BioLife Solutions Executes Supply Agreement with Celyad for CryoStor® Use in Natural Killer Receptor based T-Cell (NKR-T) Platform Targeting Solid Tumors and Blood Cancers

BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media ("BioLife" or...

CYAD : 28.88 (-0.38%)
BLFS : 9.51 (+5.08%)

Van Meerten Stock Picks

5 Great Growth Stocks
This morning I wanted to find 5 stocks that were predicted to have double digit growth in both Revenue and Earnings over the next 5 years that were also having great current performance.
LULU +1.14 , ABMD -1.06 , AAXN +2.28 , NSP +0.90 , ERI +1.00
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures were weak into the close on Thursday, down 3 to 4 1/4 cents lower in the front months. Traders were taking money off the table ahead of the extended weekend. The USDA reported a private cancelation of 132,000 of grain sorghum to unknown ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar